Fayad Lab

Fayad Lab (Cardiovascular Imaging)

Dr. Fayad’s laboratory is dedicated to the detection and prevention of cardiovascular disease and conducts interdisciplinary and discipline bridging research, from engineering to biology, which includes pre-clinical and clinical investigations. The focus of this lab is to develop and use innovative multimodality cardiovascular imaging including to study, prevent and treat cardiovascular disease, including: Magnetic Resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), as well as molecular imaging and nanomedicine. Dr. Fayad’s focus at Mount Sinai is on the noninvasive assessment and understanding of atherosclerosis (Nature 2008; 451:953-957; Nat Rev Drug Discov. 2011;10:835-52; Lancet 2012; 378:1547-1559). View the complete list publications

Early Detection and Outcomes Prediction - Use of in vivo noninvasive multimodality imaging methods for the early detection of atherosclerosis and other inflammatory diseases in humans and for cardiovascular events and outcomes prediction (NIH/NHLBI R01 LHL078667

Molecular Imaging - Development and use of novel multimodality imaging nanoparticulate systems to monitor fundamental cellular/molecular events in living subjects including patients (NIH/NIBIB R01 EB009638)

Nanomedicine - Development and use of novel targeted drug delivery nanoparticulate systems to improve the imaging and treatment of atherosclerosis (NIH/NHLBI Program of Excellence in Nanotechnology (PEN) Award, Contract #HHSN268201000045C)

Preclinical and clinical trials and drug development - Use in vivo noninvasive multimodality imaging methods (MR, PET, CT etc.) in preclinical and clinical trials for the development and testing of novel therapies to treat atherothrombosis (Industry funded)